Prostate and other male cancers:
Indications for: ELIGARD
Palliative treatment of advanced prostate cancer.
Adult Dosage:
Allow product to reach room temperature before using; inject within 30mins of mixing. Use correct formulation. Rotate inj sites. 7.5mg SC once per month; or 22.5mg SC once every 3 months; or 30mg SC once every 4 months; or 45mg SC once every 6 months.
Children Dosage:
Not established.
ELIGARD Warnings/Precautions:
May worsen metastatic vertebral lesions and/or urinary tract obstruction; monitor closely during first few weeks. Increased risk of diabetes, MI, sudden cardiac death, stroke; monitor blood glucose, HbA1c, and for signs/symptoms of CVD during therapy. Risk of QT prolongation in patients with congenital long QT syndrome, CHF, or frequent electrolyte abnormalities. Correct and monitor electrolyte abnormalities; consider monitoring ECGs. Monitor serum testosterone, PSA periodically. Embryo-fetal toxicity. Pregnancy. Nursing mothers: not recommended.
ELIGARD Classification:
GnRH analogue.
ELIGARD Interactions:
Caution with concomitant drugs known to prolong the QT interval. May interfere with pituitary-gonadal diagnostic tests.
Adverse Reactions:
Malaise, fatigue, hot flashes/sweats, testicular atrophy, local reactions (eg, burning/stinging, pain, erythema, bruising, pruritus); transient worsening of signs/symptoms (eg, bone pain, neuropathy, hematuria, bladder outlet obstruction), spinal cord compression, hyperglycemia, decreased bone density; rare: pituitary apoplexy.
How Supplied:
Single-use kit—1 (with sterile or sterile safety needle)
